Medical management of peripheral arterial disease [1]

JAMA

Volumn 296, Issue 1, 2006, Pages 41-

  Hackam, Daniel G ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PICOTAMIDE; DRUG DERIVATIVE; PHTHALIC ACID DERIVATIVE; TICLOPIDINE;

ARTERY DISEASE; CARDIOVASCULAR RISK; HUMAN; LETTER; MORBIDITY; MORTALITY; PRIORITY JOURNAL; COST BENEFIT ANALYSIS; ECONOMICS; NOTE; PERIPHERAL VASCULAR DISEASE;

ASPIRIN; COST-BENEFIT ANALYSIS; HUMANS; PERIPHERAL VASCULAR DISEASES; PHTHALIC ACIDS; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 33745600869     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.296.1.41-a     Document Type: Letter

References (4)

1. Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA. 2006;295:547-553.
2. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
3. Neri Serneri GG, Coccheri S, Marubini E, Violi F; Drug Evaluation in Atherosclerotic Vascular Disease in Diabetics (DAVID) Study Group. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J. 2004;25:1845-1852.
4. Schleinitz MD, Weiss JP, Owens DK. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis. Am J Med. 2004;116:797-806.